NCT04330040
Breast Cancer Type: HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: BRCA+
Breast Cancer Tissue:
Recruitment Status: Active, not recruiting
Phase 4
Drug Category: Misc Inhibitor
Key Eligibility Criteria:
Gender: Female
Age: Child, Adult, Older Adult
Location of Metastases:
Additional Notes: Patients with HR+ breast cancer must have been treated with a prior endocrine therapy
Exclusions:
https://ClinicalTrials.gov/show/NCT04330040